{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:05:41Z","timestamp":1783631141612,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epithelial ovarian cancers (EOCs) are a heterogenous group of neoplasms at the clinical, pathological, and molecular levels [...]<\/jats:p>","DOI":"10.3390\/ijms27031207","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:14:23Z","timestamp":1769415263000},"page":"1207","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Special Issue \u201cResistance to Therapy in Ovarian Cancers\u201d"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-268X","authenticated-orcid":false,"given":"Eros","family":"Azzalini","sequence":"first","affiliation":[{"name":"DSM\u2014Department of Molecular Sciences, University of Trieste, 34149 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-0296","authenticated-orcid":false,"given":"Serena","family":"Bonin","sequence":"additional","affiliation":[{"name":"DSM\u2014Department of Molecular Sciences, University of Trieste, 34149 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e949526","DOI":"10.12659\/MSM.949526","article-title":"Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective","volume":"31","author":"Abramiuk","year":"2025","journal-title":"Med. Sci. Monit."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17588359221148024","DOI":"10.1177\/17588359221148024","article-title":"Disparity in the era of personalized medicine for epithelial ovarian cancer","volume":"15","author":"Devlin","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.hoc.2018.07.004","article-title":"Pathogenesis, Genetics, and Genomics of Non-High Grade Serous Ovarian Cancers","volume":"32","author":"Ilenkovan","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s12094-024-03531-3","article-title":"SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023)","volume":"26","author":"Guerra","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_6","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jogc.2016.10.006","article-title":"Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up","volume":"39","author":"Panzarella","year":"2017","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ijgc-2020-001656","article-title":"Clear cell carcinoma of the ovary: A clinical and molecular perspective","volume":"31","author":"Iida","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian Cancer Prevention and Screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/GCO.0000000000000931","article-title":"Maintenance therapy for newly and recurrent epithelial ovarian cancer: Current therapies and future perspectives","volume":"36","author":"Salutari","year":"2024","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zon, A., and Bednarek, I. (2023). Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087585"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104434","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41586-025-09580-0","article-title":"Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA","volume":"647","author":"Williams","year":"2025","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"Uhlitz","year":"2022","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rivera-Serrano, M., Flores-Colon, M., Valiyeva, F., Melendez, L.M., and Vivas-Mejia, P.E. (2025). Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094012"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Huang, X., Yan, Y., Gui, A., Zhu, S., Qiu, S., Chen, F., Liu, W., Zuo, J., and Yang, L. (2022). A Regulatory Loop Involving miR-200c and NF-kappaB Modulates Mortalin Expression and Increases Cisplatin Sensitivity in an Ovarian Cancer Cell Line Model. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315300"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Harter","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ettorre, V.M., AlAshqar, A., Sethi, N., and Santin, A.D. (2025). Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers. Cancers, 17.","DOI":"10.3390\/cancers17111822"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tierno, D., Azzalini, E., Farra, R., Drioli, S., Felluga, F., Lazzarino, M., Grassi, G., Dapas, B., and Bonin, S. (2023). Nanomechanical Characterization of Ovarian Cancer Cell Lines as a Marker of Response to 2c Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087230"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12964-025-02144-9","article-title":"Mechanical cues rewire lipid metabolism and support chemoresistance in epithelial ovarian cancer cell lines OVCAR3 and SKOV3","volume":"23","author":"Karasova","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40644-025-00906-9","article-title":"CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: A multicentre study","volume":"25","author":"He","year":"2025","journal-title":"Cancer Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Maiorano, M.F., Cormio, G., Loizzi, V., and Maiorano, B.A. (2025). Artificial Intelligence in Ovarian Cancer: A Systematic Review and Meta-Analysis of Predictive AI Models in Genomics, Radiomics, and Immunotherapy. AI, 6.","DOI":"10.3390\/ai6040084"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1038\/s41467-023-41820-7","article-title":"Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer","volume":"14","author":"Woitek","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance: A Narrative Review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Eskander, R.N., Moore, K.N., Monk, B.J., Herzog, T.J., Annunziata, C.M., O\u2019Malley, D.M., and Coleman, R.L. (2023). Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1258228"},{"key":"ref_29","first-page":"a038232","article-title":"Ovarian Cancer Therapy. Cold Spring Harb","volume":"15","author":"Miao","year":"2025","journal-title":"Perspect. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14737140.2023.2236793","article-title":"Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer","volume":"23","author":"Porter","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Revythis, A., Limbu, A., Mikropoulos, C., Ghose, A., Sanchez, E., Sheriff, M., and Boussios, S. (2022). Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19148577"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2024.12.011","article-title":"Incorporating immune checkpoint inhibitors in epithelial ovarian cancer","volume":"193","author":"Bogani","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"188467","DOI":"10.1016\/j.bbcan.2020.188467","article-title":"Non-mitotic functions of polo-like kinases in cancer cells","volume":"1875","author":"Raab","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Guffanti, F., Mengoli, I., Ricci, F., Perotti, L., Capellini, E., Sala, L., Canesi, S., Wu, C.C., Fruscio, R., and Ridinger, M. (2025). Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125708"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1207\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:10:49Z","timestamp":1769663449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031207"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031207","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]}}}